SFS
KDNY

Sowell Financial Services’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Sowell Financial Services’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-331
Closed -$6K – 2982
2021
Q1 		$6K Buy
+331
New +$5.4K ﹤0.01% 2562

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sowell Financial Services's KDNY Position: Q2 2021 in Review

Sowell Financial Services sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2021, closing a stake of 331 shares — an estimated $6K sold.

Sowell Financial Services first reported a position in KDNY in Q1 2021 and held it in 1 quarter. The position peaked at $6K in Q1 2021. 89 funds tracked by Wall St. Rank hold KDNY as of Q2 2021.

  • Sowell Financial Services reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Sowell Financial Services sold 331 Chinook Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $6K.
  • Sowell Financial Services first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Sowell Financial Services's Chinook Therapeutics, Inc. Common Stock position peaked at $6K in Q1 2021.
  • 89 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Sowell Financial Services's 13F filing for Q2 2021, filed 5 Aug 2021.